512 related articles for article (PubMed ID: 29118005)
1. Redirecting T cells to hematological malignancies with bispecific antibodies.
Velasquez MP; Bonifant CL; Gottschalk S
Blood; 2018 Jan; 131(1):30-38. PubMed ID: 29118005
[TBL] [Abstract][Full Text] [Related]
2. [Cancer therapy using bispecific antibodies].
Kadowaki N
Rinsho Ketsueki; 2018; 59(10):1942-1947. PubMed ID: 30305495
[TBL] [Abstract][Full Text] [Related]
3. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
Tian Z; Liu M; Zhang Y; Wang X
J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
[TBL] [Abstract][Full Text] [Related]
4. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
Front Immunol; 2020; 11():762. PubMed ID: 32457743
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies in haematological malignancies.
Viardot A; Bargou R
Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
[TBL] [Abstract][Full Text] [Related]
6. Treatment of hematological malignancies with T cell redirected bispecific antibodies: current status and future needs.
Foster LH; Lum LG
Expert Opin Biol Ther; 2019 Jul; 19(7):707-720. PubMed ID: 31081696
[TBL] [Abstract][Full Text] [Related]
7. [Bispecific antibodies in onco-hematology: Applications and perspectives].
Barrière S; El-Ghazzi N; Garcia M; Guièze R
Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
[TBL] [Abstract][Full Text] [Related]
8. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Long M; Mims AS; Li Z
Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
[TBL] [Abstract][Full Text] [Related]
9. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
10. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Einsele H; Borghaei H; Orlowski RZ; Subklewe M; Roboz GJ; Zugmaier G; Kufer P; Iskander K; Kantarjian HM
Cancer; 2020 Jul; 126(14):3192-3201. PubMed ID: 32401342
[TBL] [Abstract][Full Text] [Related]
11. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
12. Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.
Hays P
Cancer Treat Res; 2022; 183():287-315. PubMed ID: 35551665
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.
Nagorsen D; Bargou R; Ruttinger D; Kufer P; Baeuerle PA; Zugmaier G
Leuk Lymphoma; 2009 Jun; 50(6):886-91. PubMed ID: 19455460
[TBL] [Abstract][Full Text] [Related]
14. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
15. Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
Demichelis-Gómez R; Pérez-Sámano D; Bourlon C
Curr Oncol Rep; 2019 Feb; 21(2):17. PubMed ID: 30715609
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
Bock AM; Nowakowski GS; Wang Y
Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
[TBL] [Abstract][Full Text] [Related]
17. Engineering Immune Cells for
Blanco B; Ramírez-Fernández Á; Alvarez-Vallina L
Front Immunol; 2020; 11():1792. PubMed ID: 32903593
[TBL] [Abstract][Full Text] [Related]
18. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies.
Rogala B; Freyer CW; Ontiveros EP; Griffiths EA; Wang ES; Wetzler M
Expert Opin Biol Ther; 2015 Jun; 15(6):895-908. PubMed ID: 25985814
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
20. Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.
Hoseini SS; Espinosa-Cotton M; Guo HF; Cheung NV
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]